Traders Buy Gilead Sciences (GILD) on Weakness

Investors purchased shares of Gilead Sciences, Inc. (NASDAQ:GILD) on weakness during trading on Friday. $112.97 million flowed into the stock on the tick-up and $42.15 million flowed out of the stock on the tick-down, for a money net flow of $70.82 million into the stock. Of all stocks tracked, Gilead Sciences had the 20th highest net in-flow for the day. Gilead Sciences traded down ($0.70) for the day and closed at $71.18

Several equities research analysts have recently commented on the stock. BidaskClub upgraded shares of Gilead Sciences from a “hold” rating to a “buy” rating in a research note on Thursday. Mizuho set a $94.00 target price on shares of Gilead Sciences and gave the company a “buy” rating in a research note on Friday, October 26th. Barclays boosted their target price on shares of Gilead Sciences from $90.00 to $95.00 and gave the company an “overweight” rating in a research note on Friday, October 26th. Piper Jaffray Companies downgraded shares of Gilead Sciences from an “overweight” rating to a “neutral” rating and reduced their target price for the company from $85.00 to $75.00 in a research note on Friday, October 26th. Finally, Evercore ISI restated a “buy” rating on shares of Gilead Sciences in a research note on Wednesday, October 31st. Twelve equities research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the stock. The company has an average rating of “Buy” and an average target price of $87.84.

The stock has a market capitalization of $91.20 billion, a PE ratio of 8.32, a PEG ratio of -2.73 and a beta of 1.01. The company has a debt-to-equity ratio of 1.36, a quick ratio of 3.39 and a current ratio of 3.47.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Thursday, October 25th. The biopharmaceutical company reported $1.84 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.63 by $0.21. The business had revenue of $5.60 billion for the quarter, compared to the consensus estimate of $5.44 billion. Gilead Sciences had a net margin of 7.12% and a return on equity of 39.32%. During the same quarter in the prior year, the company earned $2.27 EPS. Equities research analysts expect that Gilead Sciences, Inc. will post 6.44 earnings per share for the current year.

The business also recently declared a quarterly dividend, which will be paid on Friday, December 28th. Investors of record on Friday, December 14th will be given a dividend of $0.57 per share. The ex-dividend date is Thursday, December 13th. This represents a $2.28 annualized dividend and a yield of 3.20%. Gilead Sciences’s dividend payout ratio (DPR) is 26.64%.

In related news, Director John C. Martin sold 50,000 shares of the company’s stock in a transaction dated Tuesday, September 4th. The shares were sold at an average price of $74.16, for a total transaction of $3,708,000.00. Following the transaction, the director now owns 3,067,762 shares in the company, valued at approximately $227,505,229.92. The sale was disclosed in a filing with the SEC, which can be accessed through this link. In the last quarter, insiders have sold 150,000 shares of company stock worth $11,087,500. 1.30% of the stock is owned by corporate insiders.

A number of hedge funds and other institutional investors have recently modified their holdings of GILD. Sumitomo Mitsui Financial Group Inc. bought a new stake in Gilead Sciences during the 3rd quarter worth about $100,000. Reilly Financial Advisors LLC raised its holdings in Gilead Sciences by 98.3% during the 3rd quarter. Reilly Financial Advisors LLC now owns 1,420 shares of the biopharmaceutical company’s stock worth $110,000 after purchasing an additional 704 shares during the last quarter. Bay Colony Advisory Group Inc d b a Bay Colony Advisors bought a new stake in Gilead Sciences during the 2nd quarter worth about $132,000. Brand Asset Management Group Inc. bought a new stake in Gilead Sciences during the 2nd quarter worth about $139,000. Finally, TRUE Private Wealth Advisors bought a new stake in Gilead Sciences during the 3rd quarter worth about $174,000. Institutional investors and hedge funds own 78.09% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This report was posted by Sports Perspectives and is the property of of Sports Perspectives. If you are reading this report on another publication, it was illegally stolen and republished in violation of US and international trademark & copyright law. The original version of this report can be accessed at https://sportsperspectives.com/2018/11/09/traders-buy-gilead-sciences-gild-on-weakness.html.

About Gilead Sciences (NASDAQ:GILD)

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, and Tybost for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases.

Recommended Story: How Investors Use a Balance Sheet

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply